Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TGTX News 3 November 2025 - 11 January 2026

TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX

TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX

New York, Jan 10, 2026, 21:40 (ET) — Market closed. TG Therapeutics shares fell 6.6% on Friday to close at $28.47, down $2.03, as the biotech stock swung between $28.21 and $30.83 on about 3.3 million shares. The drop leaves traders heading into a big week for healthcare stocks as the J.P. Morgan Healthcare Conference opens Monday in San Francisco. “We have seen deals get approved that could have had more regulatory risk in the past,” JPMorgan banker Jeremy Meilman said in a Reuters report on the gathering. (Reuters) TG Therapeutics sells Briumvi, an anti-CD20 antibody approved in the United
11 January 2026
····
TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next

TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next

New York, January 9, 2026, 15:59 (EST) — Regular session TG Therapeutics (TGTX.O) shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session. The move comes with the J.P. Morgan Healthcare Conference set to kick off on Monday in San Francisco, a meeting that often pulls in fresh corporate updates and deal chatter in one tight week. The bank’s agenda shows the event runs
9 January 2026
·····
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseasesgurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S.gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis (RMS)ir.tgtherapeutics.com. It
3 November 2025
·····

Stock Market Today

Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop